State Street Corp ownership in NB3 / Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

DE ˙ DB ˙ US64125C1099

134,65 € ↑0,30 (0,22%)

2026-06-03
DEL PRIS

Security	DE:NB3 / Neurocrine Biosciences, Inc.
Institution	State Street Corp
Latest Disclosed Ownership	4,891,137 shares
Ownership	4.80%

2025-02-05 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 4,891,137 shares of Neurocrine Biosciences, Inc. (DE:NB3). This represents 4.8 percent ownership of the company. In their previous filing dated 2024-10-17 , State Street Corp had reported owning 5,148,293 shares, indicating a decrease of -4.99 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2025-02-05	2025-02-05	13G	5,148,293	4,891,137	-4.99	4.80	-5.88
2024-10-17	2024-10-17	13G		5,148,293		5.10

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	4,354,526	111,845	2.64	573,665	-4.67	0.0198
2026-02-13	2025-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	4,242,681	-103,798	-2.39	601,739	-1.38	0.0202
2025-11-14	2025-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	4,346,479	-121,787	-2.73	610,159	8.64	0.0212
2025-08-14	2025-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	4,468,266	-393,850	-8.10	561,616	4.44	0.0210
2025-05-15	2025-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	4,862,116	-29,021	-0.59	537,750	-19.46	0.0222
2025-02-14	2024-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	4,891,137	-257,156	-4.99	667,655	12.55	0.0263
2024-11-14	2024-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	5,148,293	539,936	11.72	593,186	-6.50	0.0241
2024-08-14	2024-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	4,608,357	618,396	15.50	634,433	15.29	0.0277
2024-05-15	2024-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,989,961	-73,375	-1.81	550,295	2.78	0.0246
2024-02-14	2023-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	4,063,336	226,829	5.91	535,385	24.04	0.0260
2023-11-14	2023-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,836,507	-119,992	-3.03	431,607	15.68	0.0239
2023-08-14	2023-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,956,499	156,584	4.12	373,098	-3.00	0.0196
2023-05-15	2023-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,799,915	69,729	1.87	384,627	-13.67	0.0217
2023-05-15	2022-12-31	13F/A-99	NEUROCRINE BIOSCIENCES	COM	64125C109	3,730,186	-36,535	-0.97	445,533	11.37	0.0262
2023-05-15	2022-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,730,186	-36,535		445,533		0.0262
2022-11-15	2022-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,766,721	-5,939	-0.16	400,063	8.78	0.0253
2022-08-15	2022-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,772,660	38,490	1.03	367,759	5.05	0.0220
2022-05-16	2022-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,734,170	7,029	0.19	350,078	10.28	0.0173
2022-02-14	2021-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,727,141	266,073	7.69	317,441	-4.37	0.0151
2021-11-15	2021-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,461,068	47,735	1.40	331,951	-0.07	0.0175
2021-08-16	2021-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,413,333	145,990	4.47	332,186	4.54	0.0175
2021-07-09	2021-03-31	13F/A-1	NEUROCRINE BIOSCIENCES	COM	64125C109	3,267,343	790,012	31.89	317,749	33.82	0.0182
2021-05-17	2021-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	3,267,343	790,012		317,749		0.0182
2021-02-16	2020-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	2,477,331	199,942	8.78	237,452	8.43	0.0145
2020-11-10	2020-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	2,277,389	-10,651	-0.47	218,994	-21.55	0.0150
2020-08-14	2020-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	2,288,040	-223,221	-8.89	279,141	28.43	0.0203
2020-06-19	2020-03-31	13F/A-1	NEUROCRINE BIOSCIENCES	COM	64125C109	2,511,261	57,653	2.35	217,350	-17.59	0.0190
2020-05-11	2020-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	2,511,261	57,653		217,350		19,087.7064
2020-02-06	2019-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	2,453,608	626,052	34.26	263,738	60.15	0.0181
2019-11-14	2019-09-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	1,827,556	-27,875	-1.50	164,681	5.12	0.0123
2019-08-14	2019-06-30	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	1,855,431	-162,723	-8.06	156,654	-11.89	0.0117
2019-05-15	2019-03-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	2,018,154	177,309	9.63	177,799	35.25	0.0139
2019-02-12	2018-12-31	13F	NEUROCRINE BIOSCIENCES	COM	64125C109	1,840,845	172,376	10.33	131,455	-35.92	0.0120
2018-11-09	2018-09-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	1,668,469	-105,598	-5.95	205,135	17.70	0.0158
2018-08-14	2018-06-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	1,774,067	-149,001	-7.75	174,281	9.28	0.0146
2018-05-15	2018-03-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	1,923,068	-68,109	-3.42	159,476	3.22	0.0135
2018-02-14	2017-12-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	1,991,177	-468,662	-19.05	154,497	2.49	0.0124
2017-11-14	2017-09-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,459,839	-250,357	-9.24	150,739	20.91	0.0130
2017-08-14	2017-06-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,710,196	131,141	5.08	124,666	11.63	0.0110
2017-05-15	2017-03-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,579,055	289,884	12.66	111,680	26.09	0.0100
2017-02-09	2016-12-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,289,171	145,703	6.80	88,571	-18.40	0.0083
2017-01-13	2016-09-30	13F/A-1	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,143,468	227,066	11.85	108,544	24.62	0.0109
2016-11-14	2016-09-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,143,468			108,544
2016-08-12	2016-06-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	1,916,402	-765,662	-28.55	87,101	-17.89	0.0094
2016-05-20	2016-03-31	13F/A-1	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,682,064	499,687	22.90	106,077	-14.08	0.0115
2016-05-12	2016-03-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,682,064			106,077
2016-02-16	2015-12-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,182,377	162,984	8.07	123,456	53.64	0.0135
2015-11-16	2015-09-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,019,393	-19,904	-0.98	80,354	-17.50	0.0094
2015-08-13	2015-06-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,039,297	42,558	2.13	97,398	22.83	0.0104
2015-05-15	2015-03-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	1,996,739	-90,955	-4.36	79,292	70.01	0.0081
2015-02-11	2014-12-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,087,694	-127,440	-5.75	46,639	34.35	0.0046
2014-11-12	2014-09-30	13F/A-1	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,215,134	43,254	1.99	34,714	7.70	0.0037
2014-11-10	2014-09-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,215,134			34,714
2014-08-12	2014-06-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,171,880	-71,769	-3.20	32,232	-10.77	0.0035
2014-05-15	2014-03-31	13F/A-1	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,243,649	-504,516	-18.36	36,124	40.75	0.0041
2014-05-13	2014-03-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,244,449			36,137
2014-02-06	2013-12-31	13F/A-1	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,748,165	-69,843	-2.48	25,666	-19.53	0.0029
2014-02-06	2013-12-31	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	1,556,543			11,640
2013-11-12	2013-09-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,818,008	792,090	39.10	31,897	17.67	0.0039
2013-08-08	2013-06-30	13F	NEUROCRINE BIOSCIENCES	Common equity shares	64125C109	2,025,918	2,025,918		27,108		0.0035

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.